A vaccine that comprises antigens from four strains of influenza virus, wherein two of the strains are B/Victoria/2/87-like strain and B/Yamagata/16/88-like strain and the antigens are live influenza virus. The remaining two influenza strains can be influenza A viruses. The vaccine is free of ovalbumin by growing the viruses in cell culture.